IDXX

The article explains the Zacks Earnings ESP (Expected Surprise Prediction) tool, which identifies stocks likely to beat earnings estimates by comparing analyst revisions. When combined with a Zacks Rank #3 or stronger, stocks posted positive surprises 70% of the time with ~28% average annual returns. Two medical stocks highlighted as examples are Veracyte (VCYT) with a +4.65% ESP and Idexx Laboratories (IDXX) with a +0.59% ESP, both positioned to potentially beat their upcoming earnings reports.

Idexx Laboratories (IDXX), an animal diagnostic and healthcare company, shows strong potential for another earnings beat. The company has consistently exceeded earnings estimates in recent quarters with an average surprise of 4.78%. With a positive Earnings ESP of +0.59% combined with a Zacks Rank #2 (Buy) rating, analysts predict a high probability of beating consensus estimates in the upcoming November 2, 2026 earnings report.

The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could potentially beat their upcoming earnings reports. Idexx Laboratories (IDXX) holds a #2 Buy rating with a +0.59% ESP ahead of its November 2, 2026 earnings release, while Iovance Biotherapeutics (IOVA) has a #3 Hold rating with a +22.22% ESP before reporting on November 5, 2026. Both stocks show promise for positive earnings surprises based on the Zacks ESP methodology.